EUCTR2016-003881-14-ES进行中（未招募）1 期
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer - CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,045
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Metastatic or inoperable urothelial cancer
- •- Must have at least 1 lesion with measurable disease
- •- Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
- •- No prior systemic chemotherapy treatment in the metastatic setting
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 157
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 888
排除标准
- •- Patients with disease that is suitable for local therapy administered with curative intent
- •- Patients with active brain metastases or leptomeningeal metastases
- •- Patients with active, known or suspected autoimmune disease
- •- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
研究者
相似试验
进行中（未招募）
1 期
Study of Nivolumab in Combination With Ipilimumab or with Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy in Treatment of Patients with Untreated Inoperable or Metastatic Urothelial CancerEUCTR2016-003881-14-DEBristol-Myers Squibb International Corporation1,792
进行中（未招募）
1 期
Study of Nivolumab in Combination With Ipilimumab or with Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy in Treatment of Patients with Untreated Inoperable or Metastatic Urothelial CancerEUCTR2016-003881-14-GRBristol-Myers Squibb International Corporation1,792
进行中（未招募）
1 期
Study of Nivolumab in Combination With Ipilimumab or with Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy in Treatment of Patients with Untreated Inoperable or Metastatic Urothelial Cancerntreated Unresectable or Metastatic Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-003881-14-NOBristol-Myers Squibb International Corporation1,792
招募中
3 期
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in participants with Previously Untreated Unresectable or Metastatic Urothelial CancerUrothelial Carcinoma10004994Bladder CancerNL-OMON56458Bristol-Myers Squibb70
进行中（未招募）
1 期
A study of Nivolumab combined with Ipilimumab or Standard of Care chemotherapy, versus standard of care chemotherapy in patients with previously untreated unresectable or metastatic urothelial cancer.ntreated Unresectable or Metastatic Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-003881-14-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,360